Literature DB >> 23360728

Characterization of polymeric microcapsules containing a low molecular weight peptide for controlled release.

Keith Moore1, Jennifer Amos, Jeffrey Davis, Robert Gourdie, Jay D Potts.   

Abstract

A need exists to prolong the release of rapidly metabolized peptides of a low molecular weight, while delivering this peptide without environmental interference. Previous studies have used bovine serum albumin (BSA) as a model peptide to study release characteristics from alginate microcapsules. BSA is 66 kDa in size, while the peptide of interest here, connexin-43 carboxyl-terminus mimetic peptide (αCT1), is only 3.4 kDa. Such a change in size results in a much different set of release parameters. Our overall goal is a sustained release over a 24+ h period. Prolonged application of the peptide to a wound site to investigate therapeutic effects is ideal. As a result, a diffusion method using alginate microcapsules, along with the addition of poly-l-lysine and poly-l-ornithine, has been explored. We first aimed to establish and characterize our parameters through a set of parametric tests. Variations in polymer coating, change in pH, and changes in loading ratio have previously been shown to effect release using model compounds. Here we test specific changes in these parameters to show effects on the release of αCT1. Additionally, the microcapsules were attached to several biomaterials and surgical implants by ultraviolet cross-linking to study the effectiveness of attachment and delivery. Analysis and measurements using phase contrast microscopy, scanning electron microscopy, and atomic force microscopy were used to characterize changes in microcapsule morphology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23360728     DOI: 10.1017/S143192761201389X

Source DB:  PubMed          Journal:  Microsc Microanal        ISSN: 1431-9276            Impact factor:   4.127


  7 in total

Review 1.  Cardiac to cancer: connecting connexins to clinical opportunity.

Authors:  Christina L Grek; J Matthew Rhett; Gautam S Ghatnekar
Journal:  FEBS Lett       Date:  2014-03-04       Impact factor: 4.124

2.  Targeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, αCT1, reduces VEGF-dependent RPE pathophysiology.

Authors:  Elisabeth Obert; Randy Strauss; Carlene Brandon; Christina Grek; Gautam Ghatnekar; Robert Gourdie; Bärbel Rohrer
Journal:  J Mol Med (Berl)       Date:  2017-01-28       Impact factor: 4.599

3.  A synthetic connexin 43 mimetic peptide augments corneal wound healing.

Authors:  Keith Moore; Zachary J Bryant; Gautam Ghatnekar; Udai P Singh; Robert G Gourdie; Jay D Potts
Journal:  Exp Eye Res       Date:  2013-07-20       Impact factor: 3.467

4.  Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal Neovascularization in a Mouse Model.

Authors:  Balasubramaniam Annamalai; Nathaniel Parsons; Marwa Belhaj; Carlene Brandon; Jay Potts; Bärbel Rohrer
Journal:  Transl Vis Sci Technol       Date:  2018-03-09       Impact factor: 3.283

5.  A Novel Alginate-Based Delivery System for the Prevention and Treatment of Pressure-Overload Induced Heart Failure.

Authors:  Ambrish Kumar; Marwa Belhaj; Donald J DiPette; Jay D Potts
Journal:  Front Pharmacol       Date:  2021-02-02       Impact factor: 5.810

6.  Impact of the controlled release of a connexin 43 peptide on corneal wound closure in an STZ model of type I diabetes.

Authors:  Keith Moore; Gautam Ghatnekar; Robert G Gourdie; Jay D Potts
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

Review 7.  Peptidic Connexin43 Therapeutics in Cardiac Reparative Medicine.

Authors:  Spencer R Marsh; Zachary J Williams; Kevin J Pridham; Robert G Gourdie
Journal:  J Cardiovasc Dev Dis       Date:  2021-05-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.